HYML-122

· Tarapeutics Science Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for HYML-122, covering 2024-05-14 to 2025-04-10. Get the full timeline:

Most recent: Clinical Trial Update: A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) [Phase 2]

See pricing